Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B Study of MEDI2070 in Moderate to Severe Crohn's Disease After Anti-TNFα Failure
2015-000609-38Phase 2Terminated
- Sponsor
- Allergan
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing MEDI2070 with Placebo (2 arms). Primary endpoint: CDAI remission at Week 8. Started Jan 2016; status: terminated.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-000609-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000609-38.